Although several miRNAs responsible for the regulation of channel activity have been identified [132], the design of miRNA-based therapies specifically directed against CFTR synthesis is complicated by the phenotypic variability of CF patients bearing the same genotype, by the variety of clinical manifestations and by the fact that CFTR expression is tissue-specific and time-dependent [133]. The gene discussed is CFTR; the disease is cystic fibrosis.